AbbVie Advances Immunology Pipeline with Skyrizi, Rinvoq, and Lutikizumab Data Expected in 2026
Mar 18, 2026
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.